Medically reviewed by Qin Rao, MD Metabolic dysfunction-associated steatohepatitis (MASH)—previously known as nonalcoholic ...

The drug, which is the first and the only medication approved by the FDA for treating NASH, will be marketed by the name of Rezdiffra. NASH is also known as metabolic dysfunction associated ...

Novartis has joined with Allergan in a bid to get ahead in the race to get a drug approved to treat the fatty liver disease, non-alcoholic steatohepatitis (NASH). The Swiss pharma said it is to ...

Sino Biological provides recombinant NASH-related drug targets to support drug discovery and study the interactions between these targets, offering valuable insights for developing innovative NASH ...

If resmetirom hits the mark in the upcoming MAESTRO-NASH trial, Madrigal could leapfrog rival developers and bring the first drug to market for the treatment of patients with NASH and liver ...

Finally, several other drugs have been tested specifically in NASH patients, including the weight loss medications orlistat and rimonabant and the ACE inhibitor, losartan. However, orlistat ...

Researchers at Georgetown University have developed a new drug called CTPI-2, which targets a key gene known as Slc25a1. This ...